Overcoming Clinical Challenges to Achieve Strict Glucose Control in T2DM

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: Dec 3, 2010          Expiration Date: Dec 3, 2011

Program Description

More than 60% of diabetes mellitus (DM) patients do not reach HbA1c target goals, despite overwhelming evidence that strict glucose management can reduce the development of chronic complications in these patients. The American Osteopathic Association has recognized the acute clinical need to help more patients reach target glucose goals, and has developed the Clinical Assessment Program to help its members improve patient outcomes in their practices. In addition, DM management recommendations have been updated and newer agents, such as incretin-based agents, have been included. These agents might address some of the unmet needs in the clinical care of conventional type 2 diabetes and may help lower the number of patients not safely reaching HbA1c goals. Education can bridge the gap between osteopathic physicians' current awareness of DM treatment guidelines, as well as the place and unique mechanisms of action of newer therapies in type 2 diabetes management, and the confident application of that knowledge in clinical practice.


Jeffrey S. Freeman, DO Jeffrey S. Freeman, DO, FACOI (Chair)
Professor of Internal Medicine
Chairman of Division of Endocrinology and Metabolism
Philadelphia College of Osteopathic Medicine
Philadelphia, PA

Read Biography
Ellen Miller, MD Ellen Miller, MD
Associate Professor of Medicine
Hofstra North Shore-LIJ School of Medicine
Uniondale, NY
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
Bronx, NY

Read Biography
Natasha N. Bray, DO Natasha N. Bray, DO
Assistant Professor
Department of Internal Medicine
Nova Southeastern University – College of Osteopathic Medicine
Ft. Lauderdale, FL

Read Biography

Target Audience

This program is intended for osteopathic physicians.

Educational Objectives

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate improved ability to:

  1. Explain the mechanisms of action of available incretin-based therapies and discuss their place in the treatment algorithm for DM management
  2. Review AACE and ADA recommendations for diabetes management
  3. Make therapeutic decisions (including lifestyle changes, HbA1c targets, and drug choices) based on a patient's presentation and preferences and the presence of comorbid conditions
  4. Discuss upcoming therapeutic strategies that may improve patient adherence


The AOA's continuing medical education program (CME) strives for growth of knowledge, refinement of skills, and the deepening of understanding for the osteopathic profession. The AOA Board of Trustees establishes accreditation policy for osteopathic CME sponsors. The Council on Continuing Medical Education (CCME) has been delegated authority by the AOA Board of Trustees to monitor osteopathic CME and to grant or deny Category 1 accreditation status to osteopathic CME sponsors.

To receive credit for participating in this activity complete the evaluation and post test following the completion of the activity. Participants must earn 75% or higher on the post test in order to earn credit.

Designation Statement

The American Osteopathic Association's Council on Continuing Medical Education approved the activity for 1.0 hour of Category 1-B AOA credit.

Disclosure Policy

The American Osteopathic Association and Rockpointe Corporation adhere to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of a continuing medical education program are required to disclose any relevant financial relationships with any commercial interest to AOA or Rockpointe, as well as to learners. All conflicts are identified and resolved by AOA and Rockpointe in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Jeffrey S. Freeman, DO, FACOI: Speaker: Merck, NovoNordisk, GlaxoSmithKline

Ellen Miller, MD: Speaker: Merck

Natasha N. Bray, DO: Nothing to Disclose

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Carole Drexel, PhD; Bradley Pine; Blair St. Amand; Jay Katz: Nothing to Disclose

FDA Disclosure

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

By clicking on the register button you agree that you have read and understood the information above.

By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.

Sponsored By

Supported By

Amylin Pharmaceuticals, Inc.
and Lilly USA, LLC